Palliativtherapie neuromuskulärer Erkrankungen

Zusammenfassung

Die palliativmedizinischen und hospizlichen Versorgungsstrukturen und Angeboten wurden in den vergangenen Jahren in Deutschland stark ausgebaut. Dem klinisch tätigen Neurologen steht ein weites Spektrum an palliativmedizinischen Maßnahmen zur Verfügung. In dieser Arbeit wollen wir eine Übersicht über die Therapiemöglichkeiten der wichtigsten Symptome in der letzten Lebensphase am Beispiel von Patienten mit amyotropher Lateralsklerose (ALS) stellvertretend für Menschen mit neuromuskulären Erkrankungen geben und uns an den internationalen Empfehlungen der European Academy of Neurology sowie der nationalen S3-Leitlinie “Palliativmedizin” aus dem onkologischen Leitlinienprogramm orientieren.

Summary

The hospice and palliative care structures have been strongly expanded in Germany in recent years. In the patient care sector, neurologists have access to a wide spectrum of palliative care measures. In this article, we will give an overview of the therapeutic options of the most important symptoms in the last phase of life, using the example of patients with amyotrophic lateral sclerosis (ALS) as a substitute for the most neuromuscular diseases, by taking account to the international recommendations of the European Academy of Neurology as well as the national S3 guideline “Palliative Medicine” from the Oncological Guidelines Program.

Schlüsselwörter

Neuromuskuläre Erkrankungen - amyotrophe Lateralsklerose - palliative Therapie

Keywords

Neuromuscular disease - amyotrophic lateral sclerosis - palliative care

• Literatur

• 1 HOPE. HOPE-Bericht 2015. www.hopeclara.de/download_1/index.php
• 2 S3-Leitlinie “Palliativmedizin” im Onkologischen Leitlinienprogramm. www.awmf.org/uploads/tx_szleitlinien/128–001OLl_S3_Palliativmedizin_2015–07.pdf.
• 3 Bausewein C, Roller S, Voltz R. Leitfaden Palliative Care. 5. Auflage. München: Elsevier Verlag; 2015
• 4 Oliver DJ, Borasio GD, Caraceni A, de Visser M, Grisold W, Lorenzl S, Veronese S, Voltz R. A consensus review on the development of palliative care for patients with chronic and progressive neurological disease. Eur J Neurol 2016; 23: 30-8.
• 5 Temel JS. et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-42.
• 6 Voltz R, Perrar KM. [How to react to a wish towards hastening death in palliative care?]. MMW Fortschr Med 2015; 157: 60-2.
• 7 Lorenzl S, Nubling G, Perrar KM. et al. Palliative treatment of chronic neurologic disorders. Handb Clin Neurol 2013; 118: 133-139.
• 8 Hensler M, Paul S, Abright C, Lorenzl S. [Progressive supranuclear palsy: living environment of the patients in Germany]. Nervenarzt 2011; 82 (02) 207-14.
• 9 Lorenzl S. [Multimorbidity of neurological patients in palliative care units]. Nervenarzt 2014; 85 (04) 409-16.
• 10 Grehl T. [Diagnostics and therapy for amyotrophic lateral sclerosis]. Fortschr Neurol Psychiatr 2013; 81 (10) 592-603.
• 11 Oliver DJ, Campbell C, O’brien T, Sloan R, Sykes N, Tallon C, Taylor-Horan J, Udoma M. Medication in the last days of life for motor neuron disease/amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010; 11 (06) 562-4.
• 12 Ostgathe C, Alt-Epping B, Golla H. et al. Noncancer patients in specialized palliative care in Germany: what are the problems?. Palliat Med 2011; 25 (02) 148-152.
• 13 Ostgathe C. et al. Differential palliative care issues in patients with primary and secondary brain tumours. Support Care Cancer 2010; 18 (09) 1157-63.
• 14 Van den Berg JP, Kalmijn S, Lindeman E. et al. Multidisciplinary ALS care improvesquality of life in patients with ALS. Neurology 2005; 65: 1264.
• 15 Strong M. The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 2008; 09: 323-338.
• 16 Mitsumoto H, Bromberg M, Johnston W. et al. Promoting excellence in end-of-life care in ALS. Amyotrophic Lateral Sclerosis 2005; 03: 145-154.
• 17 Oliver D, Campbell C, O’Brien T, Sloan R, Sykes N, Tallon C, Taylor-Horan J. Medication in the last days of life of MND/ALS – A study from Specialist Palliative Care providers in the UK. ALS 2009; 10 (Suppl. 01) 13.
• 18 Bourke SC, Tomlinson M, Willims TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomized controlled trial. Neurology. The Lancet 2006; 05: 140-147.
• 19 Alt-Epping B, Sitte T, Nauck F, Radbruch L. [Sedation in palliative medicine: Guidelines for the use of sedation in palliative care : European Association for Palliative Care (EAPC)]. Schmerz 2010; 24: 342-54.